Objective. To describe cumulative organ damage in juvenile dermatomyositis (JDM) patients and to identify patient characteristics and early disease variables that predict organ damage.
Introduction
Juvenile dermatomyositis (JDM) is a rare, inflammatory vasculopathic disease [1] of childhood with reported annual incidence rates of 1.9-3.2 per million children [2, 3] . The disease is characterized by proximal muscle weakness and a characteristic skin rash, but other organ systems, such as the heart, lungs, joints and gastrointestinal tract, may also be affected [4] . Before 1960, one-third of JDM-diagnosed children died of disease-related causes, and one-third became severely disabled [5] . During the past decades, the mortality rate has decreased to <2% [6, 7] , presumably due to advances in anti-inflammatory agents. However, with a longer life expectancy, JDM patients may be at increased risk of suffering disease-related damage to other organs and systems; and many patients still develop dystrophic calcifications [6, 8] and physical disability [6] .
Information about JDM outcomes is limited, and is mostly based on retrospective studies [9] . Recently, a standardized method for measuring organ damage in myositis patients, the myositis damage index (MDI), has been developed by the International Myositis Assessment and Clinical Studies Group (IMACS) [10] .
In Norway, most JDM patients are diagnosed and followed up at the Department of Rheumatology at Oslo University Hospital (OUH), Rikshospitalet. Norway has a National Population Registry that allows us to trace patients who are no longer in the hospital system.
The aims of the present study were primarily to investigate the extent of cumulative organ damage in a JDM cohort and to identify early disease variables and patient characteristics that could predict such damage. We also wanted to explore how measures of damage and disease activity changed from early disease stages through follow-up and identify predictors of calcinosis.
Patients and methods

Patients
Patients diagnosed with JDM between January 1970 and June 2006 in Norway (total population 4.7 million) were identified by search in the archive for medical records at OUH. This hospital is responsible for the care of children with rheumatic diseases in a region comprising 55% of the Norwegian population (2.6 million), and is also a referral centre for the remaining parts of the country. The Departments of Paediatrics and Rheumatology in the other regional hospitals were contacted and asked to refer any JDM patients they had seen during the past 10 years. Inclusion criteria were disease onset before 18 years, minimum disease duration of 24 months from disease onset to follow-up visit and a probable or definitive diagnosis of dermatomyositis according to the Bohan and Peter [11] criteria. A follow-up examination of all participants was carried out between September 2005 and June 2008 at the Department of Rheumatology, OUH.
Informed consent was obtained from all patients and/or parents, according to the Declaration of Helsinki. The study was approved by the Regional Ethics Committee for Medical Research. The Norwegian Directorate of Health, and the Data Security Authority, allowed use of data on deceased patients; and the causes of death were collected from the Norwegian Causes of Death Registry.
Clinical assessment and chart review
At the follow-up visit (median 16.8 years after disease onset), all patients underwent a clinical examination (muscles, skin, joints, heart and lungs) by a single physician (H.S.). Information about onset, disease course, comorbidity and use of immunosuppressive medication (including cumulative prednisolone) was obtained retrospectively from the medical records (before the follow-up visit by H.S.). When necessary, other hospitals were contacted for chart copies.
Disease onset was defined as the onset of first muscle or skin symptom clearly related to JDM. Follow-up time was defined as the time from diagnosis to the follow-up examination, and duration of untreated disease was defined as time from disease onset to first immunosuppressive medication started. In order to explore differences in drug regimes and unfavourable outcome, for certain aspects of the study, we chose to divide the cohort into those diagnosed before and after 1990 ($50% of the cohort in each group).
Disease activity score
Disease activity score (DAS), a validated tool for global disease activity in JDM [12, 13] , was scored at the follow-up visit (based on clinical assessment), and at the time of diagnosis, and 6 and 12 months post-diagnosis (based on chart reviews). The DAS has possible range 0-20 points (DAS total), and consists of two subscales: one for muscular involvement (DAS muscle, range 0-11) and another for cutaneous involvement (DAS skin, range 0-9). A low DAS represents low disease activity.
Myositis Damage Index
The MDI was used to assess cumulative and actual organ damage at the follow-up visit and damage at 6 and 12 months post-diagnosis. The MDI was developed by IMACS [10] using the pattern of the SLICC/ACR damage index for SLE [14] . Damage is defined as persistent or permanent changes present for at least 6 months, and may be the result of prior active disease, complications of therapy or comorbid condition. In the MDI, damage is defined for 11 organ systems (domains), and each domain consists of one to eight symptoms or signs (items). A score of 1 indicates that the symptom or sign (item) has been present for at least 6 months, whereas a score of 0 indicates that the symptom or sign is not present. The MDI total score is the unweighted sum of all scored items (0-1). Some items are only scored in females and/or have age limits; therefore, the numbers of scored items differ between age and gender (the maximum score is 35 in boys aged 412 years and 40 in adult women). The proposed MDI score is a fraction consisting of MDI total score divided by the number of scored items for the specific patient. The MDI has been found to reliably assess disease damage, has a good face validity and is comprehensive in adult myositis patients [10] . At the follow-up visit, the cumulative MDI score included all damage present for at least 6 months during the entire disease course and the actual MDI score included damage that was clinically detectable at the time of the visit.
Physical function
The HAQ [15] was used to measure physical function at the follow-up visit in patients 518 years, and the child HAQ (CHAQ) was used in patients <18 years [16] (range 0-3, where 0 indicates no difficulty with and 3 unable to perform daily activities). CHAQ has been validated for patients with JDM [17] .
Laboratory measurement
Values for ESR, lactate dehydrogenase, creatine kinase, aspartate aminotransferase and aldolase were extracted from the medical records at diagnosis, and at 6 and 12 months post-diagnosis, and analysed at follow-up (except for aldolase). ANA was measured by IIF, and was considered positive if the titre was 532.
Statistical analysis
Continuous, normally disturbed variables were reported as mean (S.D.), and continuous not normally disturbed variables as median (range). Differences in characteristics between two patient groups were tested by Student's unpaired, two-tailed t-test for continuous normally distributed variables, and by Mann-Whitney U-test for continuous not normally distributed variables. Chi-square test was used to test differences between two groups for categorical variables. Pearson's and Spearman's correlation coefficients (r p and r s ) were used to analyse possible correlates for normally and not normally distributed variables, respectively.
In order to analyse changes in disease activity and damage over time, a linear mixed model approach was used. The main advantage of using this approach is that patients with missing data at a single time point are retained in the analysis.
In order to identify possible risk factors for unfavourable outcomes, univariate regression analyses were performed on the relation between outcome and patient characteristics and disease variables assessed at diagnosis and 6 and 12 months post-diagnosis. Subsequent multivariate regression analysis was used in order to identify predictive factors, with backward deletion of possible predictors. Explanatory variables were included in the models if they showed an association with the outcome variable in univariate analyses (P < 0.1). Logistic analyses were used to test the predictors of calcinosis. Data on the strength of the associations were given as odds ratios (ORs) and 95% CI. Linear regression analysis was used to identify predictors of organ damage. Highly intercorrelated variables (r > 0.7) were avoided in the multiple model. Data on the strength of the associations were given as standardized .
For regression analyses, missing variables for DAS and MDI at 6 months post-diagnosis (<8%) were replaced with data from the 12-month visit for the same patient. P < 0.05 was considered as statistically significant. SPSS version 16.0 was used for statistical analyses.
Results
Patient population
Sixty-three JDM patients were identified from OUH and 4 patients after enquiry to other regional hospitals in Norway. Four (6%) of the identified patients were deceased (three males and one female), which corresponds to a mortality rate of 4.2/1000 patient-years. The causes of death were likely to be related to disease and/or anti-inflammatory agents: peritonitis, secondary to perforated gastric ulcer; pancreatitis; sepsis with disseminated intravascular coagulation; and pneumonia in a seriously affected patient. Disease duration from diagnosis to death was 0.8-16.2 years. There were no deaths among patients diagnosed after 1991.
Among the 63 living patients, 3 patients chose not to participate (all males). Thus, 60 (95%) of the living JDM patients participated in the study.
Patient and disease characteristics
According to the Bohan and Peter diagnostic criteria, 54 (90%) patients were found to have definitive and 6 (10%) patients probable dermatomyositis. Two patients developed overlapping syndromes (JDM-MCTD in one and JDM-SSc in one); both had classical JDM at disease onset and fulfilled the Bohan and Peter criteria for JDM diagnosis. The cohort at follow-up comprised 21 (35%) children or adolescents aged <18 years and 39 (65%) adults aged 518 years. Fifty-eight (97%) patients were of European origin, and two (3%) patients of Asian origin.
In the 60 JDM patients (36 females and 24 males), the mean age at first muscle or skin symptom was 8.2 (4.5) years and the median duration from disease onset to follow-up was 16.8 years (range 2.0-38.1) ( Table 1) . Fifty-eight (98%) patients had symmetrical muscle weakness during the course of the disease and 32 (53%) still had muscle weakness at follow-up due to disease activity or damage. Muscle biopsies, conducted in 56 patients, revealed changes compatible with dermatomyositis (based on evaluation by the pathologist at the time of diagnosis) in 47 (84%) patients. The most common skin rash was Gottron's sign. Calcinosis was seen in 10 (17%) patients at the time of diagnosis, in 29 (47%) patients during the disease course and persisted to follow-up in 22 (37%) patients (Table 1) . Median time from disease onset to calcinosis was 2.3 (range 0.3-10.3) years. The incidence of calcinosis between patients diagnosed before and after 1990 was not significantly different (55 vs 39%; P ¼ 0.20).
Duration of untreated disease was mean 7.4 (16.7) months, median 4 (0-119) months. Oral prednisolone treatment was started at the time of diagnosis in 50 (83%) patients, for 64% of those patients a prednisolone dose 51 mg/kg was given. During disease course, 52 (87%) patients were given prednisolone and 51 (85%) patients received at least one other immunosuppressive agent (MTX, AZA, cyclosporin, anti-malarials, i.v. immunoglobulin or infliximab) ( Table 1) . At follow-up, 18 (30%) patients were still treated with at least one immunosuppressive agent.
When comparing patients diagnosed before 1990 with those diagnosed after 1990, those diagnosed before 1990 were less commonly treated with MTX (38 vs 65%; P ¼ 0.039), methylprednisolone (3 vs 26%; P ¼ 0.027) and anti-malarial agents (21 vs 61%; P ¼ 0.001). On the other hand, more patients diagnosed before than after 1990 were treated with AZA (38 vs 7%; P ¼ 0.003). Cumulative prednisolone doses during disease course were higher for patients diagnosed before 1990 compared with those diagnosed after 1990 [14.2 (15.6) vs 6.4 (4.1)g, respectively; P ¼ 0.014], but cumulative prednisolone doses at 6 months postdiagnosis did not differ between the two groups [2.6 (1.7) vs 2.8 (1.9)g, respectively; P ¼ 0.595]. More patients diagnosed before than after 1990 were given a low start dose of prednisolone <1 mg/kg (62 vs 32%; P ¼ 0.02).
Comorbidity
Autoimmune diseases other than CTDs developed in nine (15%) of the patients (three of these patients had two such diseases). Hypothyroidism was seen in three patients, hyperparathyroidism in one, celiac disease in two and dermatitis herpetiformis in one. Three patients had psoriasis and one had a history of uveitis.
Disease activity
The change in disease activity (DAS total, DAS skin and DAS muscle) was explored using time (diagnosis, 6 and 12 months postdiagnosis and follow-up), as well as age at diagnosis and gender as fixed effects, and patient as random effect in a linear mixed model (Fig. 1A-C) . Both DAS muscle and DAS total decreased from diagnosis to 6 months, and 6 months to 1 year (all P < 0.001). DAS skin decreased from diagnosis to 6 months (P < 0.001). There was no effect of age at diagnosis or gender for the studied changes of disease activity over time (data not shown). At the follow-up visit, the median DAS total was 4.75 (range 0-13), DAS skin 4.0 (range 0-7) and DAS muscle 1.00 (range 0-8). Sixty-one per cent of the patients had a DAS total of 53 at the follow-up visit.
Organ damage
The changes in damage as assessed by MDI score were explored using time (6 and 12 months post-diagnosis and follow-up), as well as age at diagnosis and gender as fixed effects and patient as random effect in a linear mixed model (Fig. 1D ). An increase in the MDI score was observed between 1 year and the follow-up visit (P < 0.001). There was no effect of gender or age (data not shown).
After median 16.8 years, 54 (90%) patients had a cumulative MDI total score of 51 (evidence of damage in at least one organ system) and 54 (90%) also had an actual MDI total score 51. The mean cumulative and actual MDI total scores at follow-up were 4.2 (3.1) [median 3 (range 0-13)] and 3.6 (2.7) [median 3 (range 0-11)], respectively. Cumulative damage occurred most frequently in the cutaneous domain, followed by the muscular, skeletal, endocrine and pulmonary systems ( Table 2 ). The most frequently scored symptoms or signs (items) were cutaneous scarring or atrophy (63%), joint contractures (53%) and muscle weakness and calcinosis (47%). Other important types of damage included lipodystrophy (17%) and pulmonary fibrosis (5%). Only one patient had a history of malignancy (a male diagnosed with JDM at age 15 years, who 4 years later developed Hodgkin's lymphoma). Patients diagnosed before 1990 had a higher mean cumulative MDI total score at follow-up compared with those diagnosed after 1990 [5.52 (0.45) vs 2.90 (0.58); P < 0.001]. The cumulative MDI score at follow-up showed a moderate correlation with DAS total at follow-up (r s ¼ 0.446; P < 0.001).
Physical function at follow-up
Twenty-four (40%) patients had a CHAQ/HAQ score >0 at the follow-up visit (range 0-1.38). CHAQ scores >0 were found in 10 (48%) of the 21 patients aged <18 year, and HAQ scores >0 were found in 14 (36%) of 39 patients aged 518 years. The MDI score at follow-up correlated moderately with the CHAQ/HAQ disability index (r s ¼ 0.355; P ¼ 0.005). 
Prognostic factors for cumulative damage and calcinosis at follow-up
Patient characteristics and disease variables assessed within 6 months post-diagnosis were analysed as possible predictors of organ damage (Table 3) . DAS and MDI scores 6 months postdiagnosis were found to be predictors of cumulative organ damage (standardized ¼ 0.334; P ¼ 0.002 and ¼ 0.382, P < 0.001, respectively). The follow-up time was also a significant determinant of organ damage ( ¼ 0.271; P ¼ 0.010). These three variables explained 52% of the variation of the cumulative MDI score at follow-up. The same predictors (DAS, MDI score and follow-up time) were identified, when using disease variables assessed 1 year post-diagnosis; however, we were not able to identify any predictors for cumulative organ damage assessed at the time of diagnosis (data not shown).
Male gender and DAS total 6 months post-diagnosis were found to be predictors of calcinosis (OR 3.79; 95% CI 1.18, 12.15 and OR 1.20; 95% CI 1.03, 1.40, respectively) ( Table 4 ). The same predictors were identified when 10 patients who already had calcinosis at the time of diagnosis were excluded from the analysis (data not shown).
Discussion
In our JDM cohort, the majority of the patients had cumulative organ damage as measured by MDI during disease course (median 16.8 years), and damage was predicted by disease activity and the presence of damage assessed 6 months post-diagnosis. The followup time also correlated with damage at the follow-up visit. Calcinosis developed in 47% of the patients, and was predicted by male gender and persistent disease activity 6 months postdiagnosis. To our knowledge, this is the first study to describe cumulative long-term organ damage and predictive factors in a cohort of patients with JDM, utilizing standardized methods.
The vast majority of the patients in our cohort were recruited from the referral-based centre for children with paediatric rheumatological disease, and patients were evenly distributed throughout Norway. All study subjects were localized through the Norwegian population register, and 95% of the living patients participated in the follow-up examination, which is the strength of our study. This is not an epidemiological study, and we can thus not accurately estimate the incidence of JDM in Norway; however, the cases diagnosed from January 2000 to July 2006 correspond to an average annual incidence for JDM of at least 2.9 per million children aged <18 years (total population aged <18 years in Norway $1.1 million), a result comparable with the average annual incidence found in the UK, USA and Finland [2, 3, 18] .
Patient characteristics in our cohort are comparable with other hospital-or registry-based JDM cohorts with regard to the female predominance, age at diagnosis [19] [20] [21] [22] and symptom duration from disease onset to diagnosis [19] [20] [21] . Our cohort is also comparable with other hospital-based JDM cohorts with respect to medication, skin manifestations and muscle weakness at presentation [20, 21, 23] .
To our knowledge, this is the largest JDM cohort examined utilizing such a lengthy follow-up period (median 16.8 years after disease onset). All cohort subjects were clinically examined by one physician. Most of the other studies addressing outcome in JDM included few patients, or used a retrospective design without standardized methods [9] .
The main focus of this study was damage as measured by the MDI. Cumulative damage was found in 90% of our patients, but we believe the fact that all patients were examined at follow-up, and the length of time from diagnosis to follow-up contributed to this high percentage. It should be noted that most of the patients with a MDI score of 1 had only mild cutaneous changes. Damage is defined as changes in anatomy, physiology, pathology or function persistent for at least 6 months during disease course. It is known that damage might be clinically reversible, particularly in children [24] , and we found that damage was not clinically detectable at follow-up in some of the patients in whom damage was present previously. This implies that the given cumulative MDI score in some JDM patients does not reflect the actual clinical status of the patients with a lengthy disease course. Rather, it reflects the burden of damage during disease course. We therefore also chose to present damage that was clinically apparent at follow-up, and we found that 90% of the patients also had an actual MDI total score 51; but the actual mean MDI total score was lower than the cumulative MDI total score. MDI showed a moderate correlation with CHAQ/HAQ and DAS, suggesting that MDI reflects disease severity, but measures a different aspect than only disease activity (DAS) or physical disability (CHAQ/HAQ).
DAS has been recommended as a tool for global disease activity [13] , and we found it feasible to use on retrospective data. The level of and the decrease in disease activity during the first year after diagnosis is in accordance with recent studies [25, 26] . A DAS total of 43 has been reported to be associated with clinically inactive disease [25] ; using this definition we found that 61% had an active disease at follow-up.
The incidence of calcinosis in our cohort (47% during disease course and 37% at follow-up) is somewhat higher than in some cohorts [6, 27] , but comparable with others [8] . At follow-up, a substantial percentage of our patients had persistent rash (58%), muscle weakness due to disease activity or damage (53%) and physical disability (48%). Lower levels of rash and muscle weakness were found in a small study of 17 patients with follow-up examination after 18.3 years [28] and in a Canadian multi-centre study including 55 patients after a median of 7.2 years (selfreported rash and muscle weakness) [6] . The percentage of patients with physical disability was also higher in our study compared with the Canadian study. These findings may indicate that our cohort is biased towards inclusion of patients with severe disease, but can also be explained by the long follow-up time in our study, and the fact that we clinically examined all the patients at follow-up.
Compared with a study with long-term follow-up (median 9 years) of adult idiopathic myositis patients, we found lower frequencies of deaths, malignancies and lung fibrosis; whereas, the frequency of non-rheumatic autoimmune diseases was higher in our cohort [29] .
We found that high skin and muscle activity, as well as a high MDI 6 months post-diagnosis, predicted cumulative damage, reflecting that often damage is present early in the disease course. The correlation between follow-up time and organ damage is not surprising. Patients with long disease duration (23) 16 (27) 14 ( Result of multiple linear regression analysis. Correlates with organ damage in the univariate analysis (P < 0.10) were then analysed in the multivariate test, except for DAS skin and DAS muscle. These subscores also correlated with MDI (rp ¼ 0.440 and 0.444, respectively), but were not included in the multivariate analysis because of strong correlations with DAS total (rp > 0.7). The following possible predictors assessed 6 months after diagnosis did not correlate with MDI: aspartate aminotransferase, creatine kinase, ESR, positive ANA (yes/no), prednisolone dose, prednisone dose/weight at diagnosis, cumulative prednisolone dose, cumulative prednisolone dose/weight at diagnosis, started anti-inflammatory treatment and started MTX treatment (data not shown). DAS total, disease activity total score; MDI score, ratio of MDI total score to number of scored items.
might have been subjected to more cumulative damage; and they are also older and thus more likely to have comorbidity.
Calcinosis was predicted by DAS at 6 months post-diagnosis, a result supported by other studies showing that patients with sustained disease activity were more likely to develop calcinosis [27] . Also, male gender was found to be a predictor of calcinosis in our study, which has not previously been reported.
Patients diagnosed before 1990 were treated less aggressively and had more accumulated organ damage than those diagnosed later. However, the influence of treatment factors like start dose of prednisolone and early MTX treatment did not reach statistical significance in the multivariate analysis, suggesting that early disease variables were more important than treatment factors for the development of organ damage. The reason for this might be that patients with more serious disease have received more aggressive treatment, which is difficult to control for with our number of patients [26] . Low initial prednisolone doses correlated with calcinosis in the univariate but not in the multivariate analysis. Calcinosis has previously been associated with inadequate corticosteroid therapy, and also with long duration of untreated disease [21, 26, 27, 30] .
We found a significantly higher MDI total score in patients diagnosed before than after 1990. On the other hand, the frequency of calcinosis was not significantly different between the two groups. One can speculate that calcinosis is less responsive to treatment than damage in other organs; this has to be further investigated. However, we might have been unable to detect a difference in calcinosis due to the limited sample size. Another limitation of our study is the retrospective application of the diagnostic criteria and assessment of early disease variables.
In conclusion, most patients had cumulative organ damage during median 16.8 years of disease duration in our study, and persistently high disease activity and damage 6 months postdiagnosis predicted damage at follow-up. This result might warrant increased clinician awareness of which patients are at risk of developing damage, but the finding needs to be tested in prospective studies.
Rheumatology key messages
The majority of JDM patients develop cumulative organ damage after long-time follow-up. Organ damage is predicted by active muscle/skin disease and early damage 6 months post-diagnosis. Correlates with calcinosis in the univariate analysis (P < 0.10) were included in the multivariate analysis. In addition to DAS and MDI total score, the following possible predictors assessed 6 months post-diagnosis were analysed via univariate analysis: DAS muscle, DAS skin, skin ulcers, aspartate aminotransferase, creatine kinase, ESR, positive ANA (yes/ no), start dose prednisolone <1 mg/kg (yes/no), prednisolone dose, prednisone dose/weight at diagnosis, cumulative prednisolone dose, cumulative prednisolone dose/weight at diagnosis, started antiinflammatory treatment and started MTX treatment (data not shown). 
